Login to Your Account



HSCRP may be ace in hole

ROYAL flush? Gemphire shares down tubes despite LDL-C win; placebo foils

By Randy Osborne
Staff Writer

Monday, August 7, 2017

Talk turned to the finer points of phase IIb data from the trial called ROYAL-1 – in particular, success with regard to high-sensitivity C-reactive protein (hsCRP) – after Wall Street put a dent in Gemphire Therapeutics Inc., despite the fact that gemcabene achieved its primary endpoint of cholesterol lowering in the study.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription